Dr. Baliga's Internal Medicine Podcasts

A landmark study in the New England Journal of Medicine shows that hypertension control is no longer just about prescribing medications—it's about systems, teams, and sustained engagement.

Sex hormones shape cardiovascular risk in subtle yet powerful ways. From estrogen-driven changes in coagulation to formulation-specific differences in VTE risk, the nuance matters. Transdermal estradiol offers a safer path, while ethinyl estradiol reminds us that dose and route are destiny. The key is not avoidance—but precision: matching therapy to individual risk.   Three takeaways: • Formulation matters • First year matters • Patient factors matter   #Cardiology #Thrombosis #PrecisionMedicine #HormoneTherapy

  A landmark JAMA study on transcatheter tricuspid valve replacement (TTVR) offers compelling real-world evidence

  A quiet shift, yet a profound one.

What if the roots of modern surgery were written over 2,000 years ago?

A fascinating step forward in Nature—where immunology meets cardiology.

Why do GLP-1 therapies transform some patients—and barely move the needle in others?

Master athletes challenge one of medicine's most elegant assumptions: that fitness always protects.   In the Journal of the American College of Cardiology (JACC) consensus statement on athletes with abnormal cardiovascular findings, a paradox emerges—higher fitness, yet distinct patterns of risk: atrial fibrillation, coronary calcium, myocardial fibrosis.   The lesson is not to discourage exercise—but to refine our lens.   For the clinician: risk stratification must be individualized. For the athlete: performance and prudence must coexist.  

A compelling study in PLOS Medicine: sustained moderate-to-vigorous physical activity across midlife is associated with a ~50% reduction in all-cause mortality in women (target trial emulation). Not intensity, not intermittence—consistency is the signal. For clinicians, the prescription is enduring: move often, move steadily, move for life.

The origins of medicine are not merely scientific—they are deeply philosophical. In our Great Doctors Series, we begin with Dhanvantari, the divine physician of Ayurveda, emerging from myth into method. From the Ocean of Milk to the clinics of today, this episode explores how healing began as a sacred science. For students and physicians alike, it is a reminder that medicine is not just practiced—it is inherited, refined, and reimagined across centuries.

A fascinating and somewhat unsettling observation from JACC: Asia: nearly 1 in 4 STEMI patients in New Delhi had no traditional risk factors—no hypertension, diabetes, dyslipidemia, or smoking. Yet outcomes tell a different story. Despite fewer signs of heart failure at presentation, these patients had worse left ventricular dysfunction and identical in-hospital and 1-year mortality compared with those with standard risk factors. This "SMuRF-less paradox" challenges our conventional risk models. It reminds us that absence of risk factors is not absence of risk. We may need to think beyond the usual suspects—toward genetics, inflammation, lipoprotein(a), and healthcare access delays—to truly understand and prevent cardiovascular disease. A humbling lesson: treat aggressively, think broadly, and never be reassured by a "clean" risk profile.

A thoughtful and important JACC State-of-the-Art Review reframes cardiogenic shock not as a single ICU event, but as a longitudinal survivorship journey. The article highlights recovery, remission, native heart survival, PICS, HF GDMT optimization, and the need for structured multidisciplinary postshock clinics focused on function, cognition, quality of life, and recurrent risk after discharge. A timely call to move from rescue alone to rescue plus recovery.

A landmark 10-year follow-up of the HOST-EXAM trial published in The Lancet challenges a century-old assumption: aspirin may no longer be the default for lifelong secondary prevention after PCI.   Clopidogrel demonstrated a sustained reduction in ischemic and bleeding events (HR 0.86, p=0.005), with benefits that accumulated over time—yet without a mortality difference.   The implication is subtle but profound: we may be witnessing the quiet reshaping of antiplatelet strategy.   In cardiology, tradition often lingers—but data, eventually, prevails.

The New England Journal of Medicine has now given us randomized trial evidence for a question long guided more by extrapolation than by direct proof: in patients with established atherosclerotic cardiovascular disease, targeting LDL cholesterol to

New in Circulation: the 2026 AHA Dietary Guidance to Improve Cardiovascular Health distills prevention into 9 elegant features—maintain healthy weight, emphasize vegetables/fruits, choose whole grains, favor healthier proteins and unsaturated fats, minimize ultraprocessed foods, added sugars, and sodium, and avoid starting alcohol for health. Food, here, is not garnish; it is strategy.

Left atrial appendage closure—promise meets proof, and proof meets pause.   In The New England Journal of Medicine, two pivotal trials draw a nuanced arc: CHAMPION-AF shows noninferior stroke prevention with less bleeding vs direct oral anticoagulants, while CLOSURE-AF tempers enthusiasm—failing noninferiority in older, high-risk patients with meaningful procedural risk.   The message is elegant and sobering: innovation must bow to evidence, and patient selection remains paramount.   In atrial fibrillation, the art lies not in closing the appendage—but in opening judgment.

Evolocumab steps into primary prevention—quietly, convincingly. In JAMA, the VESALIUS-CV analysis shows that high-risk patients with diabetes without known atherosclerosis experienced a 31% relative reduction in first MACE (HR 0.69), with LDL-C lowered to ~52 mg/dL. The signal is clear: earlier, deeper lipid lowering matters. Yet questions remain—cost, long-term safety, and who benefits most. Are we ready to treat risk before disease declares itself?

A quiet valve, a loud message.

Cardiology stands at a quiet inflection point. We have spent decades treating plaque—yet the real opportunity lies upstream: preventing atheroma before it begins. Emerging evidence reminds us that cumulative LDL exposure, not just snapshots of risk, shapes lifelong cardiovascular destiny.   A shift is underway: → From 10-year risk to lifetime risk → From reactive care to proactive prevention → From treating disease to preserving vascular resilience Lower LDL earlier. Sustain it longer. That is not just prevention—it is strategy, science, and stewardship. #Cardiology #Prevention #Atherosclerosis #LDL #PrecisionMedicine

Resistant Hypertension remains one of the most under-recognized yet high-risk phenotypes in cardiovascular medicine. Nearly 1 in 5 treated patients meet criteria for apparent resistance—and up to half may reflect nonadherence or white-coat effect.   This concise visual series distills key insights from a recent JAMA review on diagnosis, pathophysiology, and stepwise management—including the pivotal role of spironolactone and emerging therapies like renal denervation.   Precision begins with correct classification. Treatment begins with clarity.

Sound. Mask. Mastery

Yajnavalkya: Vedic Sage • Radical Thinker • Timeless Voice

Emerging insights from Nature Spotlight on Nutrition sharpen a simple truth: what we eat matters—but when and how may matter just as much. Morning coffee aligns with lower cardiovascular mortality, plant-forward diets sculpt a favorable microbiome, early-life sugar exposure imprints lifelong risk, and not all potatoes are equal—fried forms carry harm, not the humble baked.   Nutrition is no longer advice—it is biology, timing, and destiny intertwined.

Dopamine is not just the "pleasure chemical"—it is the brain's teaching signal

A striking study in Science Translational Medicine reveals that the blood–brain barrier remains disrupted years after retirement in contact-sport athletes. This persistent leakiness is linked to systemic inflammation, complement activation, and measurable cognitive decline.   Notably, imaging of BBB dysfunction outperformed conventional blood biomarkers—offering a potential path toward early detection of CTE risk in living individuals.   The key insight: it's not single concussions, but the cumulative burden of head trauma that shapes long-term brain health.  

The thymus—long dismissed as vestigial in adults—re-emerges as a powerful biomarker of health and therapeutic response.   Two Nature (2026) studies demonstrate that AI-derived thymic health independently predicts all-cause mortality, cardiovascular death, and cancer risk, while also forecasting immunotherapy outcomes across tumor types—performing comparably to PD-L1 and tumor mutation burden.   This reframes aging as an immunologic continuum. The thymus may not just reflect health—it may define it.   #PrecisionMedicine #Immunology #CardioOncology #AIinMedicine

A quiet shift is underway in metabolic medicine. A recent Nature study shows that continuous data from wearables—heart rate, sleep, activity—combined with routine labs can detect insulin resistance years before traditional tests. Not snapshots, but a "movie" of physiology.    This opens a wider window for prevention: simpler interventions, earlier action, better outcomes. The future may lie not in waiting for thresholds, but in tracking trajectories.   #Nature #PrecisionHealth #Wearables #DiabetesPrevention #CardioMetabolic

LVAD patients are increasingly encountered in emergency rooms and ICUs, yet many clinicians remain uncertain about initial management. A recent JACC State-of-the-Art Review provides a practical framework for recognizing and treating LVAD emergencies, from pump thrombosis and right-heart failure to arrhythmias and GI bleeding. Key pearls: LVAD patients may lack a palpable pulse, Doppler is preferred for MAP measurement, and Chest compressions should not be delayed if cardiac arrest is confirmed. First check power connection Understanding pump parameters and echocardiographic clues can rapidly guide diagnosis and life-saving therapy.

Jiddu Krishnamurti challenged one of humanity's deepest assumptions—that wisdom must come from teachers, traditions, or systems. Instead, he argued that genuine understanding begins with self-observation and choiceless awareness.   In this short slide set, I summarize the life and ideas of Jiddu Krishnamurti (1895–1986)—the thinker who famously declared: "Truth is a pathless land."  

Lipids remain central to cardiovascular prevention. The 2026 ACC/AHA Dyslipidemia Guideline introduces several important shifts:   • PREVENT equations replace older ASCVD risk calculators • Lipoprotein(a) measurement recommended at least once in all adults • ApoB helps identify residual lipoprotein risk • Coronary artery calcium scoring refines treatment decisions • LDL-C targets return, with

A fascinating new study reveals a previously underappreciated pathway for tau clearance in the brain.   Researchers show that tanycytes—specialized hypothalamic glial cells—actively transport tau from cerebrospinal fluid into the bloodstream. In Alzheimer disease, these cells become fragmented and dysfunctional, impairing tau clearance and potentially accelerating neurodegeneration.   This work opens an intriguing avenue: could restoring tanycyte function enhance tau removal and slow Alzheimer progression?   A small cellular gatekeeper may hold an important clue in the battle against dementia.   Source: Sauvé F et al. Tanycytic degeneration impairs tau clearance and contributes to Alzheimer's disease pathology. Cell Press Blue, 2026.

Obesity is not simply excess weight—it is a metabolic and inflammatory state that can reshape cancer biology. Adipose tissue alters hormones, insulin signaling, inflammatory cytokines, and immune responses, creating conditions that favor tumor development. Evidence now links obesity with cancers of the breast, colon, endometrium, pancreas, liver, kidney, and esophagus. Understanding these mechanisms opens the door to precision prevention strategies, from weight management to metabolic therapies. The message from translational science is clear: metabolism and malignancy are deeply intertwined. #CancerResearch #ObesityScience #TranslationalMedicine

Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting ~37.6 million people globally, with prevalence expected to double in the coming decades.    A recent Lancet Seminar (2026) highlights several key principles shaping modern AF care:   • Stroke prevention with oral anticoagulation remains the cornerstone • Early rhythm control strategies improve cardiovascular outcomes • Catheter ablation is increasingly used as first-line therapy • Lifestyle modification—weight loss, exercise, alcohol reduction—reduces AF burden • Integrated care models such as the ABC pathway and AF-CARE improve outcomes   The future of AF management is holistic, preventive, and patient-centred.   #Cardiology #AtrialFibrillation #StrokePrevention #Electrophysiology #PrecisionMedicine

Resistant hypertension remains one of the most stubborn challenges in cardiovascular medicine.   The Bax24 phase 3 trial, published in The Lancet (2026), evaluated baxdrostat, a selective aldosterone synthase inhibitor, in patients already receiving multiple antihypertensive agents.   Key findings: • −16.6 mmHg reduction in 24-hour ambulatory SBP • −14.0 mmHg placebo-corrected difference (p

Chronic diarrhea affects approximately 6–7% of adults, and the vast majority of cases are noninfectious. The most common causes are irritable bowel syndrome with diarrhea and functional diarrhea. A systematic approach matters: • Screen with CBC, CMP, fecal calprotectin, IgA-tTG • Identify alarm features • Biopsy for microscopic colitis when needed • Start with lifestyle + low-FODMAP • Escalate to targeted therapy thoughtfully Precision in diagnosis leads to precision in therapy.   #Gastroenterology #InternalMedicine #EvidenceBasedMedicine

Jean-Paul Sartre (1905–1980) forced a generation to confront a radical idea: existence precedes essence.   We are not born with a fixed nature — we create ourselves through choices. That freedom is powerful… and unsettling.

Can lifting light weights help lift grades?

Type 1 Diabetes is more than high sugar — it is autoimmunity, absolute insulin deficiency, and lifelong vigilance.